Haematological malignancies - Clinical Trial Programme

In collaboration with the Cancer Research UK Clinical Trials Unit (CRCTU), we run an active clinical trial programme, featuring numerous NIHR Cancer Research Network-linked trials involving Birmingham-based Chief Investigators.

This involves close interaction with the CRCTU Early phase Drug Development team, and has enabled us to develop several National Cancer Research Institute-badged national trialsĀ  in Birmingham.

Current clinical trials are outlined in the table below.

Trial/Study
Therapeutic Concept
Funder
Investigator
LenaRICPhase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myelomaCTAACDr Mark Cook
PICLLe
Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-Prolymphocytic Leukaemia and Mantle Cell Lymphoma.
LLR/AstraZeneca UK Ltd
Dr Guy Pratt
TEAMMTackling Early Morbidity and Mortality in myeloma: assessing the benefit of antibiotic prophylaxis and its effect on healthcare associated infections
NIHRProfessor Mark Drayson
FIGAROFIGARO - A Randomised Trial of the FLAMSA-BU Conditioning Regimen in Patients with Acute Myeloid Leukaemia and Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation
LLRProfessor Charlie Craddock
NCRN627
ORAL AZACITIDINE (CC-486) IN AML OR MDS - A PHASE 1/2, DOSE AND SCHEDULE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF ORAL AZACITIDINE (CC-486) IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA OR MYELODYSPLASTIC SYNDROMES AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Celgene Corporation
Professor Charlie Craddock
RAvVAPhase II Randomised Trial of Azacitidine versus Azacitidine in combination with Vorinostat in patients with Acute Myeloid Leukaemia or High Risk Myelodysplastic Syndromes ineligible for Intensive Chemotherapy
LLRProfessor Charlie Craddock
ROMAZA
ROMAZA: Phase I trial of combination therapy with romidepsin and azacitidine in patients with newly diagnosed, relapsed or refractory Acute Myeloid Leukaemia ineligible for conventional chemotherapy
LLRProfessor Charlie Craddock
VIOLA
A Phase I trial of combined azactidine and lenalidomide salvage therapy in patients with acute myeloid leukaemia who relapse after allogeneic stem cell transplantation
LLRProfessor Charlie Craddock
HA-1 Vaccine StudyHA-1 Heterologous Prime Boost Vaccine Study - A phase I clinical trial of the vaccination of healthy human volunteers against the minor histocompatibility antigen (mHAg) HA-1 using a DNA and MVA 'prime/boost' regimen
LLRProfessor Paul Moss
RICAZARICAZA - PHASE II STUDY OF THE TOLERABILITY OF ADJUNCTIVE AZACITIDINE IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA
Celgene International Sarl/Cure Leukaemia Professor Charlie Craddock
Sodium ValproateSodium Valproate (Phase II study of a histone deacetylase inhibitor, sodium valproate, in AML) - Phase II Study of the Tolerability and Efficacy of the Histone Deacetylase Inhibitor Sodium Valproate given in Conjunction with ATRA (all trans retinoic acid) in Patients with Acute Myeloid Leukaemia
LLRProfessor Charlie Craddock
CMV-ACE/ASPECTA prospective phase II study to investigate the efficacy and safety of pre-emptive Cytomegalovirus Adoptive Cellular Therapy in patients receiving allogeneic haematopoietic stem cell transplant from an unrelated donor
LLR/Cell Medica Ltd
Dr Frederick Chen (Dr Karl Peggs National Lead; Dr F Chen PI for centralised immune monitoring and local cell manufacture)
CMV-IMPACTCytomegalovirus - Immunoprophylactic Adoptive Cellular Therapy Study: Phase III randomised controlled study to investigate the efficacy of CMV adoptive immunotherapy given as prophylaxisCell Medica Ltd(Dr Karl Peggs National Lead; Dr Frederick Chen local PI)
AZTECA single arm Phase II trial of the use of 5-Azacitidine for the treatment of patients with chronic graft-versus-host disease failing first line therapyLLRDr Ram Malladi
CD-ON-CAT-8015-1036A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell OriginMEDIMMUNELocal PI Frank Mussai
GS1101A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic LeukemiaGilead Sciences Inc.Local PI Dr Guy Pratt
R-CHOP vs G-CHOPPhase III trial of RCHOP vs G-CHOP in newly diagnosed Diffuse Large B-cell NHLF. Hoffmann-La Roche Ltd. Local PI Dr Guy Pratt
PADIMACPhase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT LLRDr Kwee Yong National lead; Local PI Dr Guy Pratt
BaP Single arm phase II trial assessing the safety, compliance with and activity of Bezafibrate and medroxyProgesterone acetate (BaP) as non-toxic therapy against myeloid and lymphoid cancers QEHB CharityProfessor Mark Drayson
R2WR2W: Subcutaneous Bortezomib, Cyclophosphamide and Rituximab (BCR) versus Fludarabine, Cyclophosphamide and Rituximab (FCR) for initial therapy of Waldenstrom macroglobulinaemia: a randomised phase II study. CRUKDr Rebecca Auer National lead; Local PI Dr Guy Pratt
BCD vs CCDPhase 3 trial of Bortezomib/cyclophosphamide/dex versus Carfilzomib/cyclophosphamide/dex in relapsed multiple myelomaMyeloma UKLocal PI Dr Guy Pratt
TAB-BDPhase 2 study of tabalumab in combination with bortezomib/dexamethasone in multiple myelomaLilly OncologyLocal PI Dr Guy Pratt